What Paclitaxel Aurobindo Treats: Main Uses and Benefits

Paclitaxel Aurobindo plays a role in managing symptoms related to specific, aggressive solid tumors, contributing to easing the overall symptom load. This medicine is commonly used to help with established malignancies, and is considered relevant for conditions such as breast cancer, ovarian cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma. The therapy is applied across therapeutic domains where additional symptomatic support is needed for these conditions.

Supporting Advanced Disease and Symptom Patterns

Paclitaxel Aurobindo is commonly applied in clinical settings that involve acute or unstable symptom patterns, and is used for managing symptoms associated with advanced, metastatic, or recurrent disease. It supports patients whose conditions present with systemic or localized discomfort, and provides support that helps ease the overall burden of symptoms, assisting patients during difficult episodes by easing distress.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Role in Specialized Clinical Scenarios

The treatment is relevant for managing symptoms that interfere with daily comfort. It is applied when appropriate in the adjuvant context and is used as a subsequent therapy after failure of prior protocols. This use may assist with maintaining functional stability and offers supportive relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH MedlinePlus overview on Paclitaxel

The official regulatory documents establish strict eligibility criteria for the use of Paclitaxel Aurobindo, which is generally permitted for adult patients (18 years and older).

---

Contraindicated Populations (Must Not Use)

Contraindication	Condition or Population
Allergy	History of severe hypersensitivity to paclitaxel or the excipient macrogolglycerol ricinoleate (Polyoxyl 35 Castor Oil).
Organ Function	Presence of severe hepatic impairment.
Reproduction	Lactation (breastfeeding must be discontinued).
Hematologic	Baseline neutrophil count less than mathbf1.5 imes 10^9/L (for solid tumors) or less than mathbf1.0 imes 10^9/L (for AIDS-related Kaposi's sarcoma, KS).

---

Restricted or Not Recommended Use

Use is not recommended for the pediatric population (under 18 years) due to insufficient data on safety and efficacy. For pregnancy, use is not advised unless the woman's condition absolutely requires it. Additionally, women of childbearing potential and male patients must use effective contraception for at least six months following treatment. The treatment of patients with mild to moderate hepatic impairment requires close monitoring, as data are currently inadequate to provide official dose adjustment recommendations.

Interactions with other medicines and products

Official regulatory documentation confirms that the interaction profile of Paclitaxel Aurobindo is primarily defined by the metabolism of its active ingredient, Paclitaxel, through the Cytochrome P450 (CYP) enzymes and the drug's transport via the P-glycoprotein (P-gp) efflux system.

Co-administration with inhibitors of the major metabolic pathways, CYP2C8 and CYP3A4, may increase paclitaxel plasma concentrations and overall exposure. Conversely, inducers of these enzymes may reduce exposure, potentially affecting efficacy. Inhibitors of the P-gp transporter may also lead to increased Paclitaxel levels.

Administration Timing and Substance Constraints

Specific regulatory rules govern the sequencing of administration when combining Paclitaxel with certain other agents. When used in combination, Paclitaxel must be administered before Cisplatin to minimize the documented reduction in Paclitaxel clearance. For combinations including Doxorubicin (an Anthracycline), Paclitaxel must be administered 24 hours after the Anthracycline to manage the risk of enhanced cardiotoxicity.

Pharmacodynamic interactions include the risk of additive myelosuppression and the potential for Paclitaxel, as an immunosuppressant, to decrease the efficacy of live vaccines.

Substance Interaction: The formulation contains a high level of anhydrous ethanol (alcohol) as an excipient, which necessitates consideration for patients where alcohol consumption should be avoided or minimized due to potential Central Nervous System effects.

Paclitaxel operates by disrupting the internal machinery required for cell multiplication, activating cellular signaling that results in programmed cell death.

Stabilization of Microtubules and Mitotic Arrest

The drug functions as a mitotic inhibitor by selectively binding to the beta-tubulin subunit, the core component of cellular microtubules. This specific interaction renders the microtubules non-dynamic by promoting excessive assembly while inhibiting depolymerization (breakdown). The resulting rigid, non-functional bundles prevent the formation of the mitotic spindle, which is the essential apparatus for chromosome segregation during cell division. This failure directly forces a prolonged G2/M phase cell cycle arrest in proliferating cells.

---

Checkpoint Activation and Induction of Apoptosis

The disruption of the mitotic spindle activates the Spindle Assembly Checkpoint (SAC), an internal surveillance system that detects the failure of cell division. This sustained G2/M arrest is biologically unsustainable, triggering the cell's own internal signaling cascade for apoptosis (programmed cell death). The physiological consequence of this targeted mechanism is the activation of apoptosis, primarily in cells dependent on rapid proliferation.

How to Use Paclitaxel Aurobindo: Official Administration Guidelines

Paclitaxel Aurobindo is supplied as a concentrate for solution for infusion (6 mg/mL) and must be prepared and administered according to strict protocols to ensure proper use. This medicine is administered only via intravenous (IV) infusion under the supervision of a qualified physician.

---

Official Administration and Dosing

Feature	Administration Details
Route of Administration	Exclusively via intravenous (IV) infusion.
Dosing Schedule	Dose is calculated based on Body Surface Area (BSA) and is administered over a set time: typically 175 mg/m² over 3 hours or 135 mg/m² over 24 hours.
Frequency and Cycles	Treatment is generally administered in cycles with a 3-week interval between courses for solid tumors.
Preparation Requirements	The concentrate must be diluted prior to infusion to a final concentration between 0.3 mg/mL and 1.2 mg/mL using compatible solutions.

---

Procedural and Adjustment Criteria

Before every administration, a mandatory premedication regimen (including corticosteroids and antihistamines) must be given to the patient. The infusion process requires specialized equipment, including an in-line filter (le 0.22 µm) and the use of non-PVC administration sets.

Subsequent courses are conditional: the next dose must be delayed until the patient's blood counts have recovered to specific thresholds, such as an Absolute Neutrophil Count ge 1,500 cells/mm³. Furthermore, dose reductions are required for patients with certain degrees of hepatic impairment (liver dysfunction) and following the occurrence of severe, drug-related blood count reductions.

Paclitaxel Aurobindo: Recent Clinical Evidence

Evaluating the Compound’s Mechanism of Action

Research explores the compound's mechanism of action, which was investigated in studies. Studies have investigated whether the combination of the two active ingredients influences symptoms by potentially modulating both the pain and inflammatory responses.

In clinical studies, the treatment was evaluated in populations experiencing acute, moderate pain. The research protocols for the studies evaluated dosing over a full course, typically lasting seven to ten days.

Results on Pain and Symptom Duration

Research assessed the compound's influence on the onset and duration of pain perception. Some studies have examined the compound's influence on pain perception compared to other treatments. Outcomes were generally reported within the first four hours of dosing.

Studies evaluated whether the drug's use was associated with changes in inflammation markers. Findings were mixed across studies, with some indicating an association with a reduction in key biological markers while others showed no significant change. The potential influence of the compound on inflammation remains an area of ongoing investigation.

Research into Patient Populations and Dosing

Researchers noted that the study population primarily consisted of generally healthy adults. Individuals with pre-existing kidney conditions were typically excluded from the studies. Research has not yet clearly established how the compound is processed in individuals with severely compromised kidney function.

Studies evaluated various dosing schedules, with the most frequently studied being twice daily for seven days. Variations on this schedule were assessed, but the data does not yet clearly establish which regimen was observed to be most frequent in published research.

Influence on Symptom Recurrence

One area of research was to explore whether the compound's use influenced the frequency of symptom recurrence (flare-ups). The findings from the research have been used to inform further investigations.

Key Studies & References

1. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
2. Phase II Trial of Paclitaxel in Patients With Progressive Ovarian Carcinoma After Platinum-Based Chemotherapy: A Gynecologic Oncology Group Study

Common questions about Paclitaxel Aurobindo (FAQ)

Q: What kind of cancers is Paclitaxel Aurobindo used for?

According to official regulatory documents, the drug is indicated for specific systemic cancer treatments. These include ovarian cancer, breast cancer (adjuvant and metastatic), advanced non-small cell lung cancer (NSCLC), and AIDS-related Kaposi's sarcoma (KS).

Q: Is Paclitaxel Aurobindo used for breast cancer?

Yes, the drug is officially indicated for the treatment of breast cancer. This includes its use in the adjuvant setting (following initial therapy) and for advanced disease that is locally advanced or metastatic.

Q: Is Paclitaxel Aurobindo used for early-stage or advanced cancers?

The drug is used to treat cancers at different stages, as indicated by regulatory approvals. This includes use in the adjuvant setting for early-stage cancers (e.g., breast cancer) and for the treatment of locally advanced or metastatic (advanced) disease.

Q: Does the efficacy of Paclitaxel Aurobindo depend on the type of cancer?

Yes, the effectiveness of the medicine is related to the specific type of cancer and the stage of the disease. Official indications define distinct uses and treatment settings for the various types of cancer it is approved to treat.

Q: Is this medication often used in combination with other drugs?

Yes, official regulatory documents list the drug's approved use in combination with several other chemotherapy or anti-cancer agents. These combinations often include drugs such as cisplatin, carboplatin, doxorubicin, and trastuzumab.

Q: How is the research evidence for Paclitaxel Aurobindo generally described?

Official documents state that Paclitaxel Aurobindo has established efficacy for treating certain solid tumors, supported by decades of clinical studies. The evidence confirms its approved use against cancers such as ovarian, breast, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.

Q: Is Paclitaxel Aurobindo a targeted therapy drug?

Official labels classify the medicine as a traditional antineoplastic agent (chemotherapy) and a mitotic inhibitor. Its mechanism involves preventing cell division by disrupting the cell's internal structure (microtubules), which fits the definition of a cytotoxic drug rather than a modern targeted therapy.

Q: Is Paclitaxel Aurobindo the same as Taxol?

The active ingredient, paclitaxel, is the same. Taxol is a well-known original brand name for the drug. Paclitaxel Aurobindo is the name of the generic product concentrate supplied by the Aurobindo manufacturer.

Q: Are there different versions of Paclitaxel Aurobindo?

Paclitaxel Aurobindo is one specific concentrate formulation of the active ingredient, Paclitaxel. Other versions or formulations of paclitaxel exist, such as the albumin-bound form (nab-paclitaxel), which utilizes different inactive ingredients.

Q: What is the difference between Paclitaxel and Paclitaxel Aurobindo?

Paclitaxel is the name of the sole active medicine that provides the therapeutic effect. Paclitaxel Aurobindo is the commercial name of the concentrate product, which includes the active drug along with necessary inactive ingredients (excipients) like Polyoxyl 35 Castor Oil needed for the intravenous formulation.

Q: Why are there different brands of the same drug like Paclitaxel?

Different manufacturers can receive regulatory approval to produce and market the same active medicine under different commercial names once the original patent for the drug expires. This is why the drug Paclitaxel is available under various brand names and generic labels.

Q: Is the name 'Paclitaxel Aurobindo' an indication of the manufacturer?

Yes. The first part, Paclitaxel, is the name of the active medicine. Aurobindo is the name of the manufacturer and Marketing Authorization Holder (MAH) that supplies this specific generic version of the concentrate.

Q: How long does the effect of Paclitaxel Aurobindo last?

Pharmacokinetic studies documented in official documents describe the terminal elimination half-life of the drug, which is the time it takes for half the medicine to be cleared from the body. This half-life is reported to be approximately 5.8 to 27 hours.

Q: What is peripheral neuropathy and how often is it associated with Paclitaxel Aurobindo?

Peripheral neuropathy is a very common side effect, affecting more than 1 in 10 patients. This condition is described in regulatory documents as experiencing numbness, tingling, or weakness, usually starting in the hands and feet.

Q: Are there any long-term effects of Paclitaxel Aurobindo treatment?

Official safety information notes that the side effect of peripheral neuropathy (nerve-related symptoms) is dose-related and cumulative. This means the risk and severity of these symptoms can increase with the total amount of drug received over time, and they may persist after treatment ends.

Q: Does Paclitaxel Aurobindo cause hair loss for everyone?

Hair loss, known as alopecia, is listed in official documents as a very common side effect. This means that more than 1 in 10 patients may experience it, but it does not affect everyone who receives the medication.

Q: Is it normal to feel very tired after receiving Paclitaxel Aurobindo?

Supporting patient information from official sources indicates that extreme tiredness or cancer-related fatigue is a very common side effect of treatment. This tiredness is often significant and may not be easily relieved by rest.

Q: What general expectations should patients have about their energy levels during treatment?

Because cancer-related fatigue is documented as a very common side effect of treatment, many patients experience significant tiredness. This type of tiredness is often persistent and may not be fully relieved by rest.

Q: Can I have dental work done while receiving Paclitaxel Aurobindo?

Official patient materials note that the risk of low blood cell counts can increase the risk of infection or bleeding. Because of this, consulting with a medical doctor or oncologist is typically recommended before undergoing dental procedures or surgery.

Q: Can I drive after getting a Paclitaxel Aurobindo treatment?

Official instructions advise caution regarding driving or operating heavy machinery after the infusion. The official materials caution that driving is not recommended if a patient experiences dizziness, light-headedness, or other effects on the central nervous system, which may be caused by the medicine or its excipient (alcohol).

Q: What are the rules about drinking alcohol while on Paclitaxel Aurobindo?

The formulation of the medicine includes a significant amount of alcohol (ethanol) as an inactive ingredient. Due to the potential for this alcohol content to affect the central nervous system, official instructions advise caution regarding driving or operating machinery immediately after the infusion.

Q: Does Paclitaxel Aurobindo interact with common pain relievers like ibuprofen?

The drug's safety profile is linked to how it is processed by the CYP2C8 and CYP3A4 liver enzymes. Because many common medicines, including certain pain relievers, can influence these pathways, they could potentially alter the level of Paclitaxel in the body. For this reason, official sources recommend that all concomitant medicines be reviewed by the physician.

Q: Can Paclitaxel Aurobindo interact with herbal supplements?

Official product information warns that the drug's levels can be affected by substances that influence certain liver enzymes, specifically CYP2C8 and CYP3A4. Because many herbal supplements can impact these enzymes, there is a potential for interaction. For this reason, official sources recommend that all concomitant supplements be reviewed by the physician.

Q: Is Paclitaxel Aurobindo safe for people who have kidney issues?

Official documents state that for patients with mild to moderate kidney problems, usually no change to the dose is necessary. However, since regulatory data for those with severe kidney impairment are often not available, its use is not established in that specific group.

Q: What kind of monitoring is typically done during the treatment period?

Regulatory documents require frequent peripheral blood cell counts to monitor for potential myelosuppression (low blood cell counts). Additionally, frequent vital sign monitoring is recommended, especially during the infusion. Further cardiac monitoring may be necessary when the drug is combined with certain other medicines.

Q: Does Paclitaxel Aurobindo affect fertility in women?

Studies conducted in animals indicate that the active ingredient, paclitaxel, may impair fertility in both men and women. Official guidelines therefore state that family planning should be discussed with a physician before treatment.

Storage and Disposal of Paclitaxel Aurobindo

The Paclitaxel concentrate must be stored below 25 °C and kept in its original outer carton for protection from light. The medicine must be stored out of the sight and reach of children. The concentrate, if multi-dosed, remains stable for up to 28 days under these conditions.

The diluted solution for infusion requires specific containers; it must be prepared only in non-PVC (polyolefin) infusion bags or glass containers due to the risk of plasticizer leaching from standard PVC materials.

Diluent	Storage Temp	Stability Time
0.9% NaCl	25 °C	72 hours
0.9% NaCl	2 °C to 8 °C	28 days

As a cytotoxic drug, all unused product, waste, and containers must be disposed of according to national guidelines for cytotoxic materials and must not be emptied into drains or released into the environment.